Paul-Ehrlich-Institut

Go to:

Ebo­la Vac­cines

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Erve­bo

Ebo­la Zaire-Impf­stoff (rVSVΔG-ZE­BOV-GP, lebend)

Zur ak­tiv­en Im­mu­nisierung von Per­so­n­en ab 18 Jahren Jahren zum Schutz vor der Ebo­la-Viruskrankheit (EVD, Ebo­la Virus Dis­ease), die durch das Zaire-Ebo­la-Virus verur­sacht wird.

Mer­ck Sharp & Dohme B.V.

 Mono EU/1/19/1392 11.11.2019

EPAR: Erve­bo

Wird derzeit in Deutsch­land nicht ver­mark­tet

Mv­abea

Ebo­la-Impf­stoff (MVA-BN-Fi­lo, rekom­bi­nant)

Ver­wen­dung ab dem er­sten Leben­s­jahr / Use from 1 year of age on­wards

Janssen-Cilag In­ter­na­tion­al NV, Bel­gien

 Mono EU/1/20/1445 01.07.2020

EPAR: Mv­abea

Wird derzeit in Deutsch­land nicht ver­mark­tet

Zab­de­no

Ebo­la-Impf­stoff (Ad26.ZE­BOV-GP, rekom­bi­nant)

Ver­wen­dung ab dem er­sten Leben­s­jahr / Use from 1 year of age on­wards

Janssen-Cilag In­ter­na­tion­al NV, Bel­gien

 Mono EU/1/20/1444 01.07.2020

EPAR: Zab­de­no

Wird derzeit in Deutsch­land nicht ver­mark­tet

Hints

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 477 in BAnz AT 16.02.2021 B7.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 01.03.2021